Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium-99
- Development stage
- Unknown
- Lead developer
- NorthStar Medical Radioisotopes
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intradermal
01
Overview
Technetium-99 (Tc99) is a radioactive isotope widely used as a radiopharmaceutical tracer in medical imaging and procedures, particularly in sentinel lymph node biopsy (SLNB) for various cancers. Its utility stems from its radioactive properties, which allow it to be detected by a gamma probe, thereby localizing sentinel lymph nodes. It has a relatively short half-life of approximately 6 hours, which influences its logistical handling and scheduling in clinical settings.
- Brand names
- Nano-HSANanocollTechnescan
- Other names
- technetium-99mtechnetium99mtechnetium 99mtechnetium-99technetium99technetium 99
02
Targets
Beyond the preview
Go deeper on technetium-99.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium-99.